PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Revenue of PolyNovo Limited (PNV.AX)
Revenue in 2024 (TTM): $68.77 M
According to PolyNovo Limited's latest financial reports the company's current revenue (TTM) is $68.77 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PolyNovo Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $68.77 M | $24.05 M | $2.6 M | $1.14 M | $3.51 M |
| 2023 | $43.48 M | $12.88 M | $-2,600,540 | $-3,287,333 | $-3,281,629 |
| 2022 | $27.61 M | $10.81 M | $1.03 M | $-766,956 | $-794,683 |
| 2021 | $19.43 M | $5.22 M | $-1,353,537 | $-3,032,312 | $-3,068,715 |
| 2020 | $14.76 M | $3.34 M | $-2,201,143 | $-2,774,853 | $-2,794,635 |
| 2019 | $9.36 M | $6.33 M | $-1,887,838 | $-2,125,690 | $-2,125,690 |
| 2018 | $4.37 M | $1.41 M | $-3,802,716 | $-3,981,060 | $-3,981,060 |
| 2017 | $2.41 M | $1.47 M | $-3,263,910 | $-3,335,923 | $-3,335,923 |
| 2016 | $2.18 M | $949.91 K | $-2,203,363 | $-2,166,974 | $-2,040,381 |
| 2015 | $14.89 K | $-131,310 | $-1,863,502 | $-942,479 | $-867,928 |
| 2014 | $40.11 K | $-47,854 | $-1,956,097 | $-1,960,482 | $-1,956,753 |
| 2013 | $75.01 K | $-409,179 | $-2,135,991 | $-1,046,003 | $-994,525 |
| 2012 | $ | $ | $-2,721,289 | $-1,886,408 | $-1,798,884 |
| 2011 | $258.69 K | $258.69 K | $-2,415,573 | $-2,384,393 | $-1,943,931 |
| 2010 | $81.24 K | $81.24 K | $-1,657,826 | $-1,879,199 | $-1,240,511 |
| 2009 | $ | $ | $-1,684,957 | $-1,537,438 | $-1,219,598 |
| 2008 | $ | $ | $-3,189,123 | $-2,959,518 | $-2,959,518 |
| 2007 | $2.91 K | $2.91 K | $-9,105,643 | $-8,934,156 | $-8,934,156 |
| 2006 | $119 | $119 | $-8,194,574 | $-7,526,042 | $-7,526,042 |
| 2005 | $ | $ | $-7,546,291 | $-7,173,339 | $-7,173,339 |
| 2004 | $557 | $557 | $-8,127,484 | $-6,359,643 | $ |
| 2003 | $ | $ | $-6,100,822 | $-5,710,955 | $-5,710,955 |
| 2002 | $ | $ | $-1,667,290 | $-3,819,041 | $-3,819,041 |
| 2001 | $ | $ | $-3,365,903 | $-3,379,228 | $-3,379,228 |
| 2000 | $ | $ | $-2,366,251 | $-2,374,593 | $-2,374,593 |
| 1999 | $ | $ | $-1,085,021 | $-1,089,964 | $-1,089,964 |